Danish pharmaceutical giant Novo Nordisk is taking compounding pharmacy iDexis to the Pretoria High Court. The highly anticipated legal battle will take place on June 10. The case focuses on the unauthorised scale production of semaglutide-based weight-loss injections.
Novo Nordisk wants the court to stop iDexis from manufacturing, advertising, and distributing these products. The global firm alleges that iDexis is unlawfully compounding and selling versions of its proprietary drugs. This practice creates significant public health risks.
The image displays a standard commercial delivery system. Currently, Novo Nordisk has two registered semaglutide medicines in South Africa. These are Ozempic for type 2 diabetes and Wegovy for weight loss. The South African Health Products Regulatory Authority (SAHPRA) has not registered any generic semaglutide products.
The Origins Of The Semaglutide Compounding Dispute
The upcoming court battle could reshape the domestic pharmaceutical sector. This Semaglutide Compounding Dispute tests the legal boundaries governing compounded medicines.
Licensed pharmacists typically prepare compounded medicines for individual patients. These products serve people who need a specific dose or formulation that is not commercially available. The central legal question is whether compounding pharmacies can manufacture products at scale in anticipation of demand.
Novo Nordisk South Africa manager Sara Norcross stated the company took action after receiving multiple queries. Doctors and the public were being offered a semaglutide product from an unknown source.
SAHPRA Steps In Over Product Safety
The independent pharmacy iDexis is already facing regulatory heat from SAHPRA. Last month, the regulator ordered the pharmacy to recall all products containing semaglutide and tirzepatide. SAHPRA alleged that iDexis imported ingredients illegally. The watchdog also noted a failure to comply with good manufacturing practices.
While iDexis disputed the recall, SAHPRA later confirmed it received reports of adverse side effects. Patients using the unapproved products reported several complications:
- Reflux and nausea
- Severe constipation
- Intense headaches
- Acute kidney problems in rare instances
Novo Nordisk stated that it manufactures all its own semaglutide. It does not supply the active drug substance to any compounding pharmacies in South Africa. Testing on the iDexis products allegedly revealed impurities that could compromise safety and efficacy.
The Broader Impact Of The Semaglutide Compounding Dispute
The scale of the operation has shocked the local industry. Novo Nordisk claims that iDexis sells roughly 84,500 units every month. This figure exceeds the combined sales volume of official Ozempic and Wegovy products in the country. Novo Nordisk argues this large-scale production breaches section 14(4) of the Medicines Act.
In response, iDexis denies any wrongdoing. The firm maintains it is lawfully compounding the medication. It argues its product uses the exact same 31 amino acids in the identical sequence. Furthermore, iDexis claims that South Africans have a right to access GLP-1 receptor agonists, even as global demand outstrips supply.
Pricing will also play a massive role in the legal arguments. Compounded alternatives are altering the market’s financial dynamics.
| Product Source | Monthly Cost Range (ZAR) |
|---|---|
| iDexis (via Drs Smook & Partners) | R1,250 |
| Novo Nordisk (Registered Base Price) | From R1,438 |
| iDexis (via Medi-Lean) | Up to R4,312 |
This high-stakes battle will be closely watched by healthcare professionals and legal experts across the country.
Read the Original Article (May require a subscription)